Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer

NCT02008383 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

BIOLOGICAL: Panitumumab
DRUG: Cabozantinib

Sponsor

John Strickler, M.D.

Collaborators

[object Object]